Dimerix's lead clinical program is DMX-200, which is being developed for kidney diseases and respiratory complications associated with COVID-19. The company is also developing four other product candidates and has a proprietary assay technology called ReceptorHIT. Dimerix has three Phase 3 clinical programs, including a global study in Focal Segmental Glomerulosclerosis (FSGS) patients, for which it has been granted Orphan Drug Designation by the FDA and EMA. The company has also been approached by several top 10 Pharmaceutical companies to assist with their drug discovery programs using its patented Receptor-Heteromer Investigation Technology (Receptor-HIT).